Revenue
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Solid Biosciences Inc. (SLDB)
Price$10.25Cached quote
Net income
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8.1M | $13.6M | $0 | $0 | $0 | $0 | $0 |
| Research & development | $140.3M | $96.4M | $76.6M | $78.4M | $58.7M | $64.9M | $94.7M | $58.0M | $39.9M | $20.1M |
| Operating expenses | $179.2M | $129.7M | $104.3M | $114.5M | $85.9M | $88.4M | $119.3M | $75.7M | $54.9M | $25.6M |
| Operating income | −$179.2M | −$129.7M | −$104.3M | −$106.5M | −$72.3M | −$88.4M | −$119.3M | −$75.7M | −$54.9M | −$25.6M |
| Operating margin | — | — | — | −1,315.20% | −530.50% | — | — | — | — | — |
| EBITDA | −$177.6M | −$127.3M | −$101.7M | −$104.0M | −$69.3M | −$84.5M | −$116.5M | −$74.1M | −$54.4M | −$25.5M |
| EBITDA margin | — | — | — | −1,285.45% | −508.74% | — | — | — | — | — |
| Net income | −$174.3M | −$124.7M | −$96.0M | −$86.0M | −$72.2M | −$88.3M | −$117.2M | −$74.8M | −$52.1M | −$21.5M |
| Net profit margin | — | — | — | −1,062.28% | −530.01% | — | — | — | — | — |
| Basic EPSper basic share | -$1.99 | -$3.06 | -$4.83 | -$10.10 | -$10.14 | -$25.50 | -$2,910.00 | -$2,250.00 | -$2.88 | -$10,140.00 |
| Diluted EPSper diluted share | -$1.99 | -$3.06 | -$4.83 | -$10.10 | -$10.14 | -$25.50 | -$2,910.00 | -$2,250.00 | -$2.88 | -$10,140.00 |
Owners
Reported shareholders
11.45%of listed shares
RA CAPITAL MANAGEMENT, L.P.12.04M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | 11.45%12.04M shares |
PERCEPTIVE ADVISORS LLC | 11.33%11.91M shares |
Bain Capital Life Sciences Investors, LLC | 9.33%9.81M shares |
Siren, L.L.C. | 7.32%7.69M shares |
BlackRock, Inc. | 6.60%6.93M shares |
FMR LLC | 6.54%6.88M shares |
ARMISTICE CAPITAL, LLC | 4.07%4.28M shares |
Atchinson Robert / Adage Capital Management, L.P. / Gross Phillip | ≈4.04%4.25M shares |
STATE STREET CORP | 3.97%4.18M shares |
Jupiter Topco LLC | 3.85%4.04M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.81%4.01M shares |
RTW INVESTMENTS, LP | 3.70%3.89M shares |
Deep Track Capital, LP | 3.39%3.57M shares |
FRANKLIN RESOURCES INC | 3.27%3.44M shares |
CITADEL ADVISORS LLC | 2.68%2.82M shares |
Alyeska Investment Group, L.P. | 2.17%2.28M shares |
AMERIPRISE FINANCIAL INC | 2.12%2.23M shares |
Vestal Point Capital, LP | 2.05%2.16M shares |
Redmile Group, LLC | 1.85%1.95M shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.85%1.94M shares |
Percentages use 105.13M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 18, 2026Form 4 · 10b5-1 | Cumbo AlexanderPresident and CEO | SellCommon Stock | 16.6K | $5.82 | $96.9K | 235.4K |
| Feb 18, 2026Form 4 · 10b5-1 | Hanrahan JessieChief Regulatory Officer | SellCommon Stock | 4.1K | $5.82 | $24.1K | 74.3K |
| Feb 18, 2026Form 4 · 10b5-1 | Ganot IlanDirector | SellCommon Stock · indirect | 2.7K | $5.82 | $15.5K | 27.5K |
| Feb 18, 2026Form 4 · 10b5-1 | Herzich PaulChief Technology Officer | SellCommon Stock | 3.6K | $5.82 | $21.0K | 72.6K |
| Feb 18, 2026Form 4 · 10b5-1 | Howton David TChief Operating Officer | SellCommon Stock | 7.5K | $5.82 | $43.5K | 105.1K |